Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3643
Source ID: NCT06184568
Associated Drug: Ibi362
Title: A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Acronym:
Status: ACTIVE_NOT_RECRUITING
Study Results: NO
Results:
Conditions: Type 2 Diabetes|Obesity
Interventions: DRUG: IBI362|DRUG: Semaglutide
Outcome Measures: Primary: Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss, Week 32 | Secondary: Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥15% weight loss, Week 32|Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥5% weight loss, Week 32|Proportion of subjects who achieve composite endpoint of HbA1c<6.5% and ≥5%, ≥10% or ≥15% weight loss, Week 32|Change from Baseline in HbA1c, Week 32|Change from Baseline in Fasting Plasma Glucose, Week 32|Proportion of subjects who achieve composite endpoint of HbA1c <7.0%,≤6.5% or <5.7%, Week 32|Percent Change from Baseline in Body Weight, Week 32|Change from Baseline in Waist Circumference, Week 32|Proportion of subjects who achieve ≥5%, ≥10% or ≥15% weight loss, Week 32|Change from Baseline in Blood Pressure(Systolic and Diastolic), Week 32|Percent Change from Baseline in Triglycerides, Total Cholesterol, LDL-c, HDL-c, non-HDL-c, Week 32
Sponsor/Collaborators: Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 349
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2024-02-29
Completion Date: 2026-06-30
Results First Posted:
Last Update Posted: 2025-01-15
Locations: Peking University People's Hospital, Beijing, Beijing, 100010, China
URL: https://clinicaltrials.gov/show/NCT06184568